Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

7.8K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.8K
Tumor Progression02:07

Tumor Progression

3.5K
3.5K
Skin Cancer01:30

Skin Cancer

6.6K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
6.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

5.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.6K
1.6K
Metastasis02:30

Metastasis

6.8K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antigen-specific profiling identifies T-bet<sup>+</sup> melanoma-specific CD8<sup>+</sup> T cells associated with response to neoadjuvant PD-1 blockade.

Cancer cell·2026
Same author

The Impact of Next-Generation Sequencing on Interobserver Agreement and Diagnostic Accuracy of Deep Penetrating Melanocytic Neoplasms.

Journal of cutaneous pathology·2025
Same author

Shifts in Cutaneous Melanocytic Tumor Diagnostic Terminology: Melanocytoma, MPATH-Dx V2.0 and the WHO Skin5.

Journal of cutaneous pathology·2025
Same author

Late Recurrent Spitz Melanoma With a TMEM106B :: BRAF Fusion.

The American Journal of dermatopathology·2025
Same author

Injection site reaction to teclistamab in a patient with multiple myeloma.

JAAD case reports·2025
Same author

Melanoma Diagnosis in the Mihm Era-And Beyond.

Journal of cutaneous pathology·2024
Same journal

Impact of the 2025 Endocrine Society clinical practice guideline on the diagnosis and management of primary aldosteronism for the clinical laboratory.

Pathology·2026
Same journal

Cribriform intraductal carcinoma of the prostate may have a greater prognostic impact even than Gleason grade 5 conventional prostatic adenocarcinoma.

Pathology·2026
Same journal

Bordetella pertussis: emerging epidemiology, diagnosis and management.

Pathology·2026
Same journal

Development and validation of a real-time polymerase chain reaction for the detection of Haycocknema perplexum.

Pathology·2026
Same journal

Recent advances in the understanding of TP53 in haematological malignancies.

Pathology·2026
Same journal

Concurrent renal amyloid light chain amyloidosis, light chain crystalline podocytopathy and light chain proximal tubulopathy: a case report.

Pathology·2026
See all related articles

Related Experiment Video

Updated: Mar 23, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

16.8K

Melanoma progression.

David E Elder1

  • 1Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, United States.

Pathology
|March 30, 2016
PubMed
Summary
This summary is machine-generated.

Tumor progression to malignancy is a stepwise process involving genetic changes. Intermediate lesions, while not always progressing, are key risk markers for cancer development and metastasis.

Keywords:
Melanomadysplastic naevigenomicsmetastatic melanomanaeviprogressionradial growth phasevertical growth phase

More Related Videos

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

9.7K
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

3.0K

Related Experiment Videos

Last Updated: Mar 23, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

16.8K
Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

9.7K
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

3.0K

Area of Science:

  • Oncology
  • Cancer Biology
  • Genetics

Background:

  • Tumorigenesis involves a stepwise progression from benign to malignant neoplasms.
  • Carcinogenic stimuli like UV light can initiate numerous lesions, with a subset developing atypia and becoming intermediate lesions.
  • Intermediate lesions are crucial as they can be simulants, risk markers, or potential precursors to malignancy.

Purpose of the Study:

  • To elucidate the stepwise process of tumor progression, focusing on genetic alterations.
  • To understand the role of intermediate lesions in cancer development and metastasis.
  • To explore the genetic basis of melanoma progression and metastatic potential.

Main Methods:

  • Review of the literature on tumor progression and genetic alterations.
  • Analysis of genetic changes associated with different stages of tumor development, from benign to malignant and metastatic.
  • Examination of the role of oncogenes, tumor suppressors, and copy number variations in tumorigenesis.

Main Results:

  • Tumor progression is characterized by the stepwise acquisition of genetic abnormalities, including oncogene activation and loss of tumor suppressors.
  • Intermediate lesions exhibit additional genetic alterations, distinguishing them from benign lesions and indicating a higher risk.
  • Melanoma progression involves distinct stages, with the vertical growth phase associated with metastatic potential, influenced by clinicopathological and potentially molecular attributes.

Conclusions:

  • Tumor progression is a multi-step genetic process, with intermediate lesions representing critical junctures.
  • While most precursor lesions do not progress, their genetic landscape provides insights into malignancy development.
  • Understanding these stages, particularly in melanoma, is vital for risk assessment and developing effective therapeutic strategies against advanced and resistant cancers.